Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) IDO Inhibitors Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global IDO Inhibitors Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Dual IDO1/TDO inhibitors
      • 1.3.3 Covalent IDO inhibitors
    • 1.4 Market Segment by Application
      • 1.4.1 Global IDO Inhibitors Market Share by Application (2019-2025)
      • 1.4.2 Metastatic Melanoma
      • 1.4.3 Metastatic Pancreatic Cancer
      • 1.4.4 mCRPC
      • 1.4.5 Malignant Glioma
      • 1.4.6 Astrocytoma
      • 1.4.7 Breast Cancer
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global IDO Inhibitors Market Size
      • 2.1.1 Global IDO Inhibitors Revenue 2014-2025
      • 2.1.2 Global IDO Inhibitors Sales 2014-2025
    • 2.2 IDO Inhibitors Growth Rate by Regions
      • 2.2.1 Global IDO Inhibitors Sales by Regions 2014-2019
      • 2.2.2 Global IDO Inhibitors Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 IDO Inhibitors Sales by Manufacturers
      • 3.1.1 IDO Inhibitors Sales by Manufacturers 2014-2019
      • 3.1.2 IDO Inhibitors Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 IDO Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 IDO Inhibitors Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global IDO Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.3 IDO Inhibitors Price by Manufacturers
    • 3.4 Key Manufacturers IDO Inhibitors Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into IDO Inhibitors Market
    • 3.6 Key Manufacturers IDO Inhibitors Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Dual IDO1/TDO inhibitors Sales and Revenue (2014-2019)
      • 4.1.2 Covalent IDO inhibitors Sales and Revenue (2014-2019)
    • 4.2 Global IDO Inhibitors Sales Market Share by Type
    • 4.3 Global IDO Inhibitors Revenue Market Share by Type
    • 4.4 IDO Inhibitors Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global IDO Inhibitors Sales by Application

    6 United States

    • 6.1 United States IDO Inhibitors Breakdown Data by Company
    • 6.2 United States IDO Inhibitors Breakdown Data by Type
    • 6.3 United States IDO Inhibitors Breakdown Data by Application

    7 European Union

    • 7.1 European Union IDO Inhibitors Breakdown Data by Company
    • 7.2 European Union IDO Inhibitors Breakdown Data by Type
    • 7.3 European Union IDO Inhibitors Breakdown Data by Application

    8 China

    • 8.1 China IDO Inhibitors Breakdown Data by Company
    • 8.2 China IDO Inhibitors Breakdown Data by Type
    • 8.3 China IDO Inhibitors Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World IDO Inhibitors Breakdown Data by Company
    • 9.2 Rest of World IDO Inhibitors Breakdown Data by Type
    • 9.3 Rest of World IDO Inhibitors Breakdown Data by Application
    • 9.4 Rest of World IDO Inhibitors Breakdown Data by Countries
      • 9.4.1 Rest of World IDO Inhibitors Sales by Countries
      • 9.4.2 Rest of World IDO Inhibitors Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Pfizer
      • 10.1.1 Pfizer Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of IDO Inhibitors
      • 10.1.4 IDO Inhibitors Product Introduction
      • 10.1.5 Pfizer Recent Development
    • 10.2 Bristol-Myers Squibb
      • 10.2.1 Bristol-Myers Squibb Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of IDO Inhibitors
      • 10.2.4 IDO Inhibitors Product Introduction
      • 10.2.5 Bristol-Myers Squibb Recent Development
    • 10.3 Kyowa Hakko Kirin
      • 10.3.1 Kyowa Hakko Kirin Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of IDO Inhibitors
      • 10.3.4 IDO Inhibitors Product Introduction
      • 10.3.5 Kyowa Hakko Kirin Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 IDO Inhibitors Sales Channels
      • 11.2.2 IDO Inhibitors Distributors
    • 11.3 IDO Inhibitors Customers

    12 Market Forecast

    • 12.1 Global IDO Inhibitors Sales and Revenue Forecast 2019-2025
    • 12.2 Global IDO Inhibitors Sales Forecast by Type
    • 12.3 Global IDO Inhibitors Sales Forecast by Application
    • 12.4 IDO Inhibitors Forecast by Regions
      • 12.4.1 Global IDO Inhibitors Sales Forecast by Regions 2019-2025
      • 12.4.2 Global IDO Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
      Indoleamine-2,3-dioxygenase (IDO) is one of the many immune checkpoints in tumor immune escape. Inhibiting IDO will help researchers restore immune system responses, which in turn, will help identify and destroy cancer cells. In addition to transforming the approach to treat advanced melanoma, the successful entry of IDO inhibitors in the market will also help transform the treatment of non-small lung cancer, triple-negative breast cancer, and bladder cancer with the existing therapies. Currently, most of the IDO inhibitors under investigation are in the very nascent development stage and focusing on R&D, pharmaceutical companies are making huge investments through collaboration agreements. For instance, one of the major pharmaceutical companies Pfizer has partnered with iTeos Therapeutics for the development of undisclosed IDO1 and tryptophan 2,3-dioxygenase 2 (TDO2) inhibitors.
      In 2019, the market size of IDO Inhibitors is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for IDO Inhibitors.

      This report studies the global market size of IDO Inhibitors, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the IDO Inhibitors sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Pfizer
      Bristol-Myers Squibb
      Kyowa Hakko Kirin
      ...

      Market Segment by Product Type
      Dual IDO1/TDO inhibitors
      Covalent IDO inhibitors

      Market Segment by Application
      Metastatic Melanoma
      Metastatic Pancreatic Cancer
      mCRPC
      Malignant Glioma
      Astrocytoma
      Breast Cancer

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the IDO Inhibitors status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key IDO Inhibitors manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of IDO Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now